Ebola in the US 2025
Ebola virus disease remains one of the most deadly infectious diseases known to modern medicine, with mortality rates that can reach 80-90% in certain outbreaks, making it one of the highest fatality infectious diseases affecting humans. The Centers for Disease Control and Prevention reports that Orthoebolaviruses can cause serious and often deadly disease, with a mortality rate as high as 80 to 90 percent, though this varies significantly by virus species, outbreak circumstances, and available medical care. The Ebola mortality rate has historically fluctuated dramatically across different outbreaks, with recent meta-analysis data showing a pooled case fatality rate of 60.6% globally from 1976 to 2022.
The Ebola mortality rate in the US 2025 context is particularly relevant given ongoing surveillance of international outbreaks and preparedness efforts for potential importation of cases. Current outbreak monitoring includes the Democratic Republic of the Congo outbreak declared in September 2025, which as of September 2025 reported 58 suspected or confirmed cases with 20 deaths, representing approximately a 34.5% case fatality rate for this specific outbreak. While no cases of Ebola have been reported in the United States related to current outbreaks, the CDC maintains Level 1 Travel Health Notices and comprehensive preparedness protocols to address any potential imported cases, given the historically high mortality rates associated with this hemorrhagic fever virus.
Interesting Ebola Facts and Latest Statistics in the US 2025
| Ebola Fact Category | Verified 2025 Statistical Data | Source Verification |
|---|---|---|
| Global Pooled Mortality Rate | 60.6% | Meta-analysis 1976-2022 |
| Historical Range | 25-90% | WHO outbreak data |
| Current Average | Around 50% | WHO 2025 estimates |
| Zaire Species (Untreated) | Up to 90% | CDC historical data |
| Current DRC Outbreak | 20 deaths of 58 cases | CDC September 2025 |
| DRC Outbreak Mortality | 34.5% | Calculated rate |
| US Cases 2025 | Zero reported | CDC surveillance |
| 2014-2016 West Africa | 11,323 deaths | WHO final count |
| 2014-2016 Total Cases | 28,646 cases | WHO final count |
| West Africa Mortality | 39.5% | Calculated from WHO data |
| Healthcare Worker Deaths | 4 deaths (current DRC) | CDC September 2025 |
| DRC Total Outbreaks | 16 outbreaks since 1976 | CDC historical tracking |
| Recent Stabilized Rate | 61.0% (2014-2022) | Meta-analysis findings |
| Treatment Availability | FDA-approved vaccine | Zaire species only |
Data Source: CDC Ebola Situation Summary, WHO Fact Sheets, Meta-analysis Journal Publications 2023
The interesting Ebola facts and latest statistics in the US 2025 demonstrate the highly variable but consistently severe mortality rates associated with different Ebola virus species and outbreak circumstances. The global pooled mortality rate of 60.6% from comprehensive meta-analysis represents nearly five decades of outbreak data, while the current DRC outbreak showing 34.5% mortality reflects improved medical response and treatment capabilities compared to historical outbreaks.
The 2014-2016 West Africa epidemic with 11,323 deaths among 28,646 cases resulted in a 39.5% overall mortality rate, significantly lower than historical averages due to international medical intervention and improved supportive care. The range of 25-90% mortality rates across different outbreaks highlights how factors such as virus species, healthcare infrastructure, early detection, and medical intervention dramatically influence Ebola mortality rates. The zero reported US cases in 2025 reflects effective international surveillance and domestic preparedness, though the CDC maintains active monitoring of global outbreaks to prevent importation and potential domestic transmission.
Historical Ebola Mortality Rate Trends in the US 2025
| Time Period | Major Outbreaks | Mortality Rate | Cases and Deaths |
|---|---|---|---|
| 1976-1990 | Early DRC outbreaks | 80-90% | Limited cases, high mortality |
| 1990-2010 | Sporadic outbreaks | 70-80% | Small outbreak numbers |
| 2014-2016 | West Africa epidemic | 39.5% | 28,646 cases, 11,323 deaths |
| 2018-2020 | DRC outbreak | Variable | Major outbreak response |
| 2014-2022 Period | Recent analysis | 61.0% stabilized | Meta-analysis data |
| 2025 Current | DRC Kasai outbreak | 34.5% | 58 cases, 20 deaths |
Data Source: CDC Outbreak History, WHO Epidemic Data, Journal Meta-analysis 2023
The historical Ebola mortality rate trends in the US 2025 perspective shows a general decline from the 80-90% mortality rates seen in early outbreaks to more recent rates in the 30-60% range, reflecting improved understanding of supportive care and outbreak response capabilities. Early outbreaks from 1976-1990 showed consistently high mortality rates due to limited medical intervention and delayed outbreak recognition in remote areas.
The 2014-2016 West Africa epidemic marked a turning point with a 39.5% overall mortality rate, demonstrating that intensive international medical response could significantly reduce Ebola mortality rates compared to historical norms. The meta-analysis showing 61.0% stabilized mortality for the 2014-2022 period suggests that while improvements have occurred, Ebola mortality rates remain substantial. The current 2025 DRC outbreak showing 34.5% mortality may reflect continued improvements in early detection, case management, and available treatments, though outbreak circumstances and healthcare access continue to significantly influence mortality outcomes.
Ebola Species-Specific Mortality Rates in the US 2025
| Ebola Virus Species | Scientific Name | Historical Mortality Range | Treatment Availability |
|---|---|---|---|
| Zaire Ebolavirus | Orthoebolavirus zairense | Up to 90% | FDA-approved vaccine |
| Sudan Ebolavirus | Orthoebolavirus sudanense | Below 50% | Limited treatment options |
| Taï Forest Ebolavirus | Orthoebolavirus taiense | Non-fatal in humans | Research stage |
| Bundibugyo Ebolavirus | Orthoebolavirus bundibugyoense | Variable | Limited data |
| Bombali Ebolavirus | Orthoebolavirus bombaliense | Unknown in humans | Research stage |
| Reston Ebolavirus | Orthoebolavirus restonense | Non-pathogenic to humans | Not applicable |
Data Source: CDC Ebola Species Information, WHO Technical Reports, Virology Research Data
The Ebola species-specific mortality rates in the US 2025 reveal dramatic differences in pathogenicity between different Orthoebolavirus species, with implications for outbreak response and treatment approaches. Zaire Ebolavirus (Orthoebolavirus zairense) represents the most deadly species with mortality rates up to 90%, responsible for major outbreaks including the 2014-2016 West Africa epidemic and current DRC outbreaks. This species is the only one with an FDA-approved vaccine available for prevention.
Sudan Ebolavirus shows significantly lower mortality rates below 50%, as demonstrated in recent outbreaks where case fatality remained substantially lower than Zaire species outbreaks. Taï Forest Ebolavirus has caused only one known human infection without fatal outcome, while Reston Ebolavirus appears non-pathogenic to humans despite affecting non-human primates. The species-specific mortality differences highlight why accurate laboratory identification is crucial for outbreak response, treatment decisions, and mortality rate predictions during Ebola emergencies.
Geographic Ebola Mortality Rate Variations in the US 2025
| Geographic Region | Recent Outbreaks | Mortality Rate | Healthcare Infrastructure |
|---|---|---|---|
| West Africa (2014-2016) | Guinea, Sierra Leone, Liberia | 39.5% | International medical support |
| DRC Eastern Regions | Multiple outbreaks | Variable | Limited healthcare access |
| DRC Kasai Province (2025) | Current outbreak | 34.5% | Remote area, limited access |
| Uganda (Recent) | Sudan virus outbreaks | Below 50% | Improved response capacity |
| United States | No current cases | N/A | Advanced medical infrastructure |
| International Importation | Isolated cases | Lower rates | Advanced supportive care |
Data Source: CDC Geographic Tracking, WHO Regional Data, Outbreak Response Reports
The geographic Ebola mortality rate variations in the US 2025 demonstrate how healthcare infrastructure, outbreak response capacity, and geographic accessibility significantly influence mortality rates. West Africa’s 2014-2016 epidemic achieved a 39.5% mortality rate despite affecting countries with limited healthcare infrastructure, primarily due to massive international medical intervention and establishment of specialized treatment centers.
DRC’s eastern regions have experienced multiple outbreaks with variable mortality rates influenced by security situations, healthcare access, and population density. The current Kasai Province outbreak showing 34.5% mortality reflects the challenges of remote geographic locations with limited transportation networks that complicate medical response. Uganda’s experience with Sudan virus outbreaks demonstrates lower mortality rates partly due to different virus species and improved national outbreak response capacity. The United States maintains zero current cases but would likely achieve lower mortality rates than global averages due to advanced medical infrastructure and immediate access to intensive supportive care.
Treatment Impact on Ebola Mortality Rates in the US 2025
| Treatment Category | Availability | Mortality Impact | Evidence Level |
|---|---|---|---|
| Supportive Care | Universal standard | Reduces mortality significantly | Well-established |
| Ebola Vaccine (rVSV-ZEBOV) | FDA-approved for Zaire species | Prevention, not treatment | Proven effective |
| Monoclonal Antibodies | Limited availability | Mortality reduction | Clinical evidence |
| Antiviral Treatments | Investigational | Under evaluation | Research stage |
| Intensive Care Support | Resource-dependent | Major mortality reduction | Well-documented |
| Early Case Detection | Variable by setting | Improves outcomes | Epidemiological evidence |
Data Source: CDC Treatment Guidelines, WHO Clinical Protocols, Medical Literature Reviews
The treatment impact on Ebola mortality rates in the US 2025 shows that while no specific cure exists, multiple interventions can significantly reduce mortality rates compared to untreated cases. Supportive care including fluid replacement, electrolyte management, and symptom control represents the foundation of Ebola treatment and has contributed to the decline in mortality rates from historical highs of 80-90% to current ranges of 30-60%.
FDA-approved Ebola vaccine (rVSV-ZEBOV) provides prevention for Zaire Ebolavirus but doesn’t treat active disease, though it has dramatically reduced outbreak sizes and secondary transmission. Monoclonal antibody treatments have shown promise in clinical trials for reducing mortality rates, particularly when administered early in disease progression. Intensive care support available in developed healthcare systems like the United States can potentially achieve mortality rates significantly lower than global averages, though the small number of cases in developed countries limits definitive data on this advantage.
Current 2025 Ebola Outbreaks and Mortality Analysis
| Current Outbreak | Location | Cases | Deaths | Mortality Rate | Response Status |
|---|---|---|---|---|---|
| DRC Kasai Province | Bulape, Mweka health zones | 58 cases | 20 deaths | 34.5% | Active response |
| Healthcare Worker Impact | DRC outbreak | 4 HCW deaths | Included above | High-risk occupation | Protection protocols |
| United States | Surveillance active | 0 cases | 0 deaths | N/A | Preparedness maintained |
| Global Monitoring | WHO/CDC systems | Active surveillance | Real-time tracking | Variable by outbreak | International coordination |
Data Source: CDC Ebola Situation Summary September 2025, WHO Situation Reports
The current 2025 Ebola outbreaks and mortality analysis focuses primarily on the Democratic Republic of the Congo outbreak in Kasai Province, which as of September 2025 reported 58 suspected or confirmed cases with 20 deaths, resulting in a 34.5% case fatality rate. This mortality rate is lower than historical averages, potentially reflecting improved outbreak response capabilities and earlier case detection, though the outbreak remains active with frequent changes to case counts expected.
The 4 healthcare worker deaths included in the overall count highlight the continued occupational risks for medical personnel treating Ebola patients, despite improved infection prevention and control protocols. United States surveillance maintains zero reported cases related to current outbreaks, with CDC Level 1 Travel Health Notices and preparedness protocols in place. The 16th Ebola outbreak in DRC since 1976 demonstrates the persistent nature of Ebola transmission in endemic areas, while international mortality rate monitoring provides real-time data for public health response and risk assessment.
US Preparedness and Ebola Mortality Prevention in 2025
| Preparedness Component | Implementation Status | Mortality Prevention Impact | Resource Allocation |
|---|---|---|---|
| CDC Surveillance Systems | Fully operational | Early detection reduces mortality | Continuous monitoring |
| Hospital Isolation Protocols | Nationwide standards | Prevents secondary transmission | Healthcare training |
| Laboratory Diagnostics | Rapid testing capability | Early diagnosis improves outcomes | CDC laboratory network |
| Medical Countermeasures | Stockpiled vaccines/treatments | Available for imported cases | Strategic reserves |
| International Partnerships | Active collaboration | Reduces global outbreak risk | CDC overseas presence |
| Healthcare Worker Training | Ongoing programs | Reduces occupational mortality | Professional education |
Data Source: CDC Preparedness Reports, Healthcare Readiness Assessments, Public Health Infrastructure Analysis
The US preparedness and Ebola mortality prevention in 2025 reflects comprehensive systems designed to minimize mortality rates in the event of imported cases or domestic transmission. CDC surveillance systems provide early warning capabilities that can reduce mortality rates through rapid case identification and isolation, preventing the delayed diagnosis that historically contributed to higher death rates in outbreak settings.
Nationwide hospital isolation protocols and healthcare worker training programs address the occupational mortality risks demonstrated by the 4 healthcare worker deaths in the current DRC outbreak. Rapid laboratory diagnostics and available medical countermeasures position the United States to achieve mortality rates potentially lower than the 34.5% seen in current international outbreaks. International partnerships through CDC’s overseas presence contribute to global mortality rate reduction while reducing the risk of importation to the United States, where advanced medical infrastructure could provide optimal supportive care for any imported cases.
Age-Specific Ebola Mortality Patterns in the US 2025
| Age Group | Mortality Risk Level | Case Fatality Rate | Clinical Characteristics |
|---|---|---|---|
| Under 5 years | Very High | 80-90% | Rapid progression, severe dehydration |
| 5-15 years | Lower | 40-50% | Better survival outcomes |
| 16-40 years | Moderate | 50-60% | Variable outcomes |
| 41-65 years | Higher | 70-80% | Increased mortality with age |
| Over 65 years | Very High | 80-90% | Comorbidities compound risk |
| Healthcare Workers | Occupational Risk | Variable | 4 deaths in current outbreak |
Data Source: WHO Age-Specific Analysis, CDC Epidemiological Studies, West Africa Outbreak Data
The age-specific Ebola mortality patterns in the US 2025 reveal significant variation in case fatality rates across age groups, with the lowest mortality rates (40-50%) occurring in children aged 5-15 years and the highest rates (80-90%) in very young children under 5 and elderly adults over 65. This U-shaped mortality curve reflects both immunological factors and clinical management challenges, with infants and elderly patients experiencing rapid disease progression and complications.
Middle-aged adults (41-65 years) show mortality rates of 70-80%, while young adults (16-40 years) maintain more moderate 50-60% case fatality rates. Healthcare workers face significant occupational mortality risk, as demonstrated by the 4 healthcare worker deaths in the current DRC outbreak, though their mortality rates can vary based on infection control protocols and early treatment access. These age-specific mortality patterns inform clinical management strategies and highlight the need for age-appropriate supportive care protocols in any potential US Ebola cases.
Ebola Transmission Dynamics and Mortality Correlation in the US 2025
| Transmission Parameter | Value Range | Mortality Connection | Outbreak Impact |
|---|---|---|---|
| Basic Reproduction Number (R0) | 1.3-2.0 typical | Higher R0 may correlate with severity | Outbreak size predictor |
| West Africa R0 (2014-2016) | Guinea: 1.71, Liberia: 1.83, Sierra Leone: 2.02 | Varied with mortality rates | Country-specific patterns |
| Incubation Period | 2-21 days (average 8-10) | Longer incubation may indicate milder disease | Early detection window |
| Infectious Period | Several days to weeks | Prolonged shedding increases transmission | Secondary case generation |
| Superspreading Events | 20% of cases cause 80% transmission | May involve sickest patients | Funeral-related transmission |
| Case Detection Delay | Variable by setting | Delayed detection increases mortality | Healthcare system capacity |
Data Source: Systematic Review Meta-analysis, West Africa Epidemiological Studies, WHO Technical Reports
The Ebola transmission dynamics and mortality correlation in the US 2025 demonstrate complex relationships between transmission parameters and case fatality rates. The basic reproduction number (R0) ranging from 1.3-2.0 is lower than many respiratory viruses but sufficient for sustained transmission, with higher R0 values potentially correlating with more severe outbreaks and higher mortality rates. West Africa’s country-specific R0 values (Guinea: 1.71, Liberia: 1.83, Sierra Leone: 2.02) showed variation that aligned with different mortality rate patterns across these countries.
Superspreading events, where 20% of cases generate 80% of transmission, often involve the sickest patients near death, creating direct links between high mortality cases and increased transmission risk. Case detection delays significantly impact both transmission control and mortality outcomes, as delayed diagnosis reduces access to supportive care and increases transmission risk. The incubation period of 2-21 days provides a window for contact tracing and preventive measures, while longer incubation periods may indicate less severe disease courses with potentially lower mortality rates.
Viral Load and Ebola Mortality Correlation in the US 2025
| Viral Load Category | Copies/ml Range | Case Fatality Rate | Clinical Significance |
|---|---|---|---|
| Low Viral Load | <10^6 copies/ml | Lower mortality | Better survival outcomes |
| High Viral Load | >10^6 copies/ml | Higher case fatality | Poor prognosis indicator |
| Peak Viremia | Up to 10^9 copies/ml | Near 100% mortality | Overwhelming infection |
| Early Detection | Lower baseline levels | Improved survival | Treatment window |
| Disease Progression | Increasing viral load | Mortality predictor | Clinical monitoring |
| Treatment Response | Declining viral load | Survival indicator | Therapeutic effectiveness |
Data Source: Clinical Studies on Viral Load, WHO Laboratory Guidelines, Treatment Response Studies
The viral load and Ebola mortality correlation in the US 2025 reveals strong predictive relationships between viral burden and case fatality rates. Patients with viral loads exceeding 10^6 copies/ml demonstrate significantly higher case fatality rates compared to those with lower viral loads below this threshold. Peak viremia levels reaching 10^9 copies/ml are associated with near 100% mortality, indicating overwhelming viral replication that exceeds the body’s capacity for immune response and tissue repair.
Early detection when viral loads remain relatively low provides the optimal treatment window and correlates with improved survival outcomes. Disease progression monitoring through serial viral load measurements serves as a mortality predictor, with persistently increasing levels indicating poor prognosis. Treatment response can be assessed through declining viral load patterns, serving as an early indicator of potential survival before clinical improvement becomes apparent. This viral load-mortality correlation emphasizes the importance of rapid diagnostic capabilities and frequent monitoring in any US Ebola case management protocols.
International Ebola Mortality Rate Comparisons in the US 2025
| Country/Region | Outbreak Period | Cases | Deaths | Mortality Rate | Healthcare Context |
|---|---|---|---|---|---|
| Guinea (West Africa) | 2014-2016 | 3,814 cases | 2,544 deaths | 66.7% | Limited infrastructure |
| Liberia (West Africa) | 2014-2016 | 10,678 cases | 4,810 deaths | 45.0% | International support |
| Sierra Leone (West Africa) | 2014-2016 | 14,124 cases | 3,956 deaths | 28.0% | Extensive medical aid |
| DRC Eastern (2018-2020) | 2018-2020 | 3,470 cases | 2,287 deaths | 65.9% | Security challenges |
| DRC Kasai (Current 2025) | 2025 ongoing | 58 cases | 20 deaths | 34.5% | Remote location |
| Uganda (Recent) | 2022-2023 | 164 cases | 77 deaths | 47.0% | Sudan virus species |
Data Source: WHO Situation Reports, CDC Country-Specific Data, National Health Ministry Reports
The international Ebola mortality rate comparisons in the US 2025 reveal significant variation in case fatality rates across different countries and outbreak circumstances. Sierra Leone achieved the lowest mortality rate (28.0%) during the 2014-2016 West Africa epidemic due to extensive international medical support and treatment center establishment, while Guinea showed the highest rate (66.7%) in the same epidemic, reflecting differences in healthcare infrastructure and response capacity.
Liberia’s 45.0% mortality rate during the same period demonstrated intermediate outcomes with international assistance. DRC’s eastern outbreak (2018-2020) showed 65.9% mortality complicated by security challenges that limited medical access. The current DRC Kasai outbreak with 34.5% mortality reflects improved response capabilities despite remote location challenges. Uganda’s recent Sudan virus outbreak with 47.0% mortality demonstrates both species differences and improved national response capacity, providing context for potential US mortality rates that would likely be lower due to advanced medical infrastructure.
Ebola Outbreak Duration and Mortality Patterns in the US 2025
| Outbreak Characteristic | Duration/Timeline | Mortality Impact | Response Effectiveness |
|---|---|---|---|
| Average Outbreak Duration | 6-18 months | Early deaths highest | Response learning curve |
| West Africa (2014-2016) | 2+ years | 11,323 total deaths | Prolonged international response |
| DRC Eastern (2018-2020) | 22 months | 2,287 deaths | Security complications |
| Early Phase Mortality | First 2-3 months | Highest case fatality rates | Limited preparedness |
| Mid-Phase Mortality | Months 3-12 | Declining mortality | Response optimization |
| Late Phase Mortality | Final months | Lowest case fatality rates | Established protocols |
Data Source: WHO Timeline Analysis, Outbreak Response Reports, Historical Outbreak Studies
The Ebola outbreak duration and mortality patterns in the US 2025 demonstrate consistent relationships between outbreak timeline and case fatality rates. Early phase mortality typically shows the highest case fatality rates during the first 2-3 months due to limited preparedness, delayed recognition, and absence of established treatment protocols. The West Africa epidemic’s 2+ year duration with 11,323 total deaths illustrated how prolonged outbreaks can accumulate massive mortality despite declining case fatality rates over time.
Mid-phase mortality typically shows declining case fatality rates as response systems optimize, treatment centers establish capacity, and healthcare workers gain experience. Late phase mortality often achieves the lowest case fatality rates once protocols are established and resources are fully deployed. The DRC eastern outbreak’s 22-month duration with 2,287 deaths demonstrated how security challenges can extend outbreak duration and maintain higher mortality rates throughout. This pattern suggests that rapid US response capabilities could potentially minimize the high early phase mortality typical of Ebola outbreaks.
Economic Impact of Ebola Mortality in the US 2025
| Economic Category | Impact Scale | Mortality Connection | US Implications |
|---|---|---|---|
| West Africa Economic Loss | $2.8 billion GDP impact | 11,323 deaths reduced workforce | Economic disruption model |
| Healthcare System Costs | $3.6 billion response | Mortality prevention focus | Resource allocation needs |
| Individual Treatment Cost | $18,500-30,000 per case | Intensive care requirements | US healthcare costs |
| Contact Tracing Costs | $1,000-5,000 per contact | Mortality prevention | Public health investment |
| Outbreak Response Costs | $100 million+ per outbreak | Mortality reduction priority | Emergency preparedness |
| Productivity Loss | Years of life lost | High mortality age groups | Economic productivity impact |
Data Source: World Bank Economic Analysis, CDC Cost Studies, Healthcare Economic Research
The economic impact of Ebola mortality in the US 2025 reflects the substantial costs associated with both mortality itself and mortality prevention efforts. West Africa’s $2.8 billion GDP impact from the 2014-2016 epidemic directly correlated with the 11,323 deaths and associated workforce reduction, creating long-term economic consequences beyond the immediate health crisis. Healthcare system costs of $3.6 billion for the international response emphasized mortality prevention as the primary economic priority.
Individual treatment costs ranging from $18,500-30,000 per case in developed healthcare systems reflect the intensive care requirements needed to reduce mortality rates. Contact tracing costs of $1,000-5,000 per contact represent investments in mortality prevention through transmission control. US preparedness costs would likely focus on maintaining capabilities to achieve lower mortality rates than international averages, with emergency response investments designed to minimize both case numbers and case fatality rates through rapid deployment of advanced medical countermeasures.
Future Outlook for Ebola Mortality Rates
The Ebola mortality rate outlook suggests continued gradual improvement from current levels, though substantial mortality will likely persist due to the inherent virulence of Orthoebolavirus species. Treatment advances including improved monoclonal antibody therapies and antiviral agents under development may further reduce mortality rates beyond the current 60.6% global average, particularly in settings with access to advanced medical care. Vaccine expansion beyond the current FDA-approved vaccine for Zaire species could provide prevention options for other Ebola virus species, potentially reducing outbreak frequency and associated mortality.
Healthcare infrastructure improvements in endemic regions may contribute to reducing the geographic mortality disparities currently observed between resource-limited and resource-rich settings. Early warning systems and rapid response protocols developed through ongoing outbreak experiences may enable more prompt intervention, reducing the delays that historically contributed to higher mortality rates. However, the remote geographic locations of many outbreaks and the resource constraints in affected regions suggest that Ebola mortality rates will remain substantially higher than those of most infectious diseases. International preparedness efforts and continued research into Ebola pathogenesis and treatment offer hope for further mortality reduction, though the fundamental challenge of managing a disease with case fatality rates ranging from 25-90% will persist as a major global health security concern.
Disclaimer: The data research report we present here is based on information found from various sources. We are not liable for any financial loss, errors, or damages of any kind that may result from the use of the information herein. We acknowledge that though we try to report accurately, we cannot verify the absolute facts of everything that has been represented.
